Helsinn akynzeo fda approval?

Yes. Akynzeo (netupitant/palonosetron) is FDA-approved.

- Indication: For adults to prevent chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy. It’s used as part of a prevention regimen, typically alongside dexamethasone.
- How it’s given: A single fixed-dose capsule taken about 1 hour before chemotherapy (netupitant 300 mg + palonosetron 0.5 mg). Dexa­methasone dosing is adjusted per the label because netupitant inhibits CYP3A4, which can affect steroid levels.
- Who it’s for: Approved for adults; not approved for pediatric use in the U.S.
- Mechanism: Fixed-dose combo of an NK1 receptor antagonist (netupitant) and a 5-HT3 receptor antagonist (palonosetron).
- Common side effects: Headache, fatigue, constipation, hiccups, etc.

If you’d like, I can look up the exact FDA approval date and pull the official label details.